BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16256237)

  • 1. AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing core-corona type polymeric nanospheres.
    Akagi T; Ueno M; Hiraishi K; Baba M; Akashi M
    J Control Release; 2005 Dec; 109(1-3):49-61. PubMed ID: 16256237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice.
    Akagi T; Kawamura M; Ueno M; Hiraishi K; Adachi M; Serizawa T; Akashi M; Baba M
    J Med Virol; 2003 Feb; 69(2):163-72. PubMed ID: 12683403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice.
    Kawamura M; Wang X; Uto T; Sato K; Ueno M; Akagi T; Hiraishi K; Matsuyama T; Akashi M; Baba M
    J Med Virol; 2005 May; 76(1):7-15. PubMed ID: 15778965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
    Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
    Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice.
    Kawamura M; Naito T; Ueno M; Akagi T; Hiraishi K; Takai I; Makino M; Serizawa T; Sugimura K; Akashi M; Baba M
    J Med Virol; 2002 Mar; 66(3):291-8. PubMed ID: 11793379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
    Jiang JQ; Patrick A; Moss RB; Rosenthal KL
    J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.
    Koopman G; Bogers WM; van Gils M; Koornstra W; Barnett S; Morein B; Lehner T; Heeney JL
    J Med Virol; 2007 May; 79(5):474-82. PubMed ID: 17385685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
    McBurney SP; Young KR; Ross TM
    Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Bråve A; Hallengärd D; Schröder U; Blomberg P; Wahren B; Hinkula J
    Vaccine; 2008 Sep; 26(40):5075-8. PubMed ID: 18450334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160.
    VanCott TC; Kaminski RW; Mascola JR; Kalyanaraman VS; Wassef NM; Alving CR; Ulrich JT; Lowell GH; Birx DL
    J Immunol; 1998 Feb; 160(4):2000-12. PubMed ID: 9469464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine.
    Hamajima K; Hoshino Y; Xin KQ; Hayashi F; Tadokoro K; Okuda K
    Clin Immunol; 2002 Jan; 102(1):12-8. PubMed ID: 11781062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.
    Zhang H; Huang Y; Fayad R; Spear GT; Qiao L
    J Virol; 2004 Aug; 78(15):8342-8. PubMed ID: 15254206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration.
    Caputo A; Castaldello A; Brocca-Cofano E; Voltan R; Bortolazzi F; Altavilla G; Sparnacci K; Laus M; Tondelli L; Gavioli R; Ensoli B
    Vaccine; 2009 Jun; 27(27):3605-15. PubMed ID: 19464541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.